FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE** COMMISSION

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response:	0.5								

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
$\cup$	obligations may continue. See
	Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				' '			_							
Name and Address of Reporting Person*     Oren Ilan					2. Issuer Name <b>and</b> Ticker or Trading Symbol Roivant Sciences Ltd. [ ROIV ]									(Cr	neck all ap	ationship of Reporting Person(s) to Issuer ( all applicable)					
					-									$\dashv$		Director		10% Ov			
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/03/2023										Offic belo	cer (give title w)		Other (s below)	specify		
C/O ROIVANT SCIENCES LTD.						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
7TH FLOOR, 50 BROADWAY					4. 17 anonamoni, bate of original Field (worth/bay/rear)									Line)							
,											X Form filed by One Reporting Person										
(Street) LONDON X0 SW1H 0DB				0DB											Form filed by More than One Reporting Person						
LONDON AU SWIII UDD					Rule 10b5-1(c) Transaction Indication																
(City)	/C+	ato) (7	7in)		Talisaction malcation																
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Table	I - Noı	n-Deriva	tive Se	ecur	ities	Acq	uired,	Dis	posed of	, or	Ben	eficia	ally Ow	ned					
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)					Execution D			Date,	Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. and 5)				Secur Bene Owne Follor	ficially ed wing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		A) or D)	Price		rted action(s) . 3 and 4)					
Common Shares 07/03/2						2023			A		1,472(1)	)	Α	<b>\$0</b> <sup>(1</sup>	) (	53,585	]	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			tion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and			8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amo or Num of Sha	ber							

## **Explanation of Responses:**

1. Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

By: /s/ Jo Chen, as Attorneyin-Fact for Ilan Oren

07/06/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.